Q2 highlights: Strong sales growth, +34% in constant currencies
Continued strong sales in USA
Instrument sales increasing globally
Consumables up +6% vs 2020, but still slow due to COVID-19 restrictions, in particular in Asia
Disturbances in the supply chain impact profitability
Good progress with our strategic development projects
COVID
recovery
Positive R12 trends for both instruments and consumables
Boule Diagnostics
July 19, 2021
Delivered on plans in Q2
H1 2021 priorities
Increase digital marketing and enhanced support to distributors
Start-upnew distributors in EMEA
Start local production in Russia
Ramp-upproduction of new OEM reagents
Industrialization of new product platform
On-planOn-plan
On-plan
Instrument sales drive growth
Net sales in constant currencies up +34% YoY, +9% QoQ
High share of instrument sales
Product and regional mix as well as supply chain disturbances pressure gross margin
OPEX up 4.1 MSEK
Increased sales and marketing activities, recruitment costs
Investments in new platform 13 MSEK
Boule Diagnostics
July 19, 2021
Financials Q2
Net sales, MSEK
Gross margin
110,7
41.7%
YoY Growth
EBIT-margin
22.1%
2.1%
Op. cash-flow, MSEK
8.2
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Boule Diagnostics AB published this content on 19 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 July 2021 07:50:03 UTC.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
